Gliadel Marketing For Newly-Diagnosed Glioma Will Highlight Survival Benefit
This article was originally published in The Gray Sheet
Executive SummaryGuilford Pharmaceuticals' marketing of Gliadel Wafer for use in patients undergoing surgery for newly-diagnosed malignant glioma will highlight survival benefit, the company said after receiving the supplemental indication
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.